<DOC>
	<DOCNO>NCT02671435</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalation dose-expansion study evaluate safety , tolerability , antitumor activity , PK , pharmacodynamics , immunogenicity Durvalumab ( MEDI4736 ) combination IPH2201 Adult Subjects select advanced solid tumor .</brief_summary>
	<brief_title>A Study Durvalumab ( MEDI4736 ) IPH2201 Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , multicenter , open-label , single-arm dose-escalation dose-expansion study durvalumab combination IPH2201 evaluate safety , tolerability , PK , immunogenicity , pharmacodynamics , antitumor activity adult subject select advance solid tumor . The study consist 2 part : dose escalation dose expansion . Subjects receive durvalumab IPH2201 via 2 separate IV infusion . Subjects receive durvalumab IPH2201 unacceptable toxicity , documentation confirm progressive disease ( PD ) , documentation subject withdrawal another reason .</detailed_description>
	<criteria>1 . Subjects must histologic documentation advanced recurrent metastatic cancer . 2 . Subjects must receive progressed refractory least one line standard systemic therapy recurrent/metastatic setting , select advance solid tumor . 3 . Subjects must least one lesion measurable RECIST v1.1 Exclusion Criteria 1 . Prior treatment immunotherapy agent . Prior treatment antitumor vaccine may permit upon discussion medical monitor . 2 . Prior participation clinical study include durvalumab alone combination , study registrational intent analysis primary endpoint yet complete 3 . Receipt conventional investigational anticancer therapy within 4 week prior first dose durvalumab IPH2201 4 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . Concurrent use hormone noncancerrelated condition acceptable . Local treatment isolate lesion palliative intent acceptable beyond DLTevaluation period prior consultation agreement medical monitor . 5 . Current prior use immunosuppressive medication within 14 day first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>